Instil Bio, Inc.

TIL Healthcare Biotechnology

In the quarter to June 2026, EPS grew 80.6%, free cash flow grew 68.6% and total debt was flat, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years.

5.91 0.22 −3.59%
Market cap
$41.6M
P/E
0.0×
Fwd P/E
—
Dividend yield
—
F-score
n/a
Altman Z
n/a
Beneish M
n/a
Dividend safety
n/a
Older periods Sep '25 Dec '25 Mar '26 Jun '26
ROE

+8 more TTM periods

(50.60%) (50.39%) (37.07%) (25.33%)
ROA
(31.00%) (30.56%) (21.64%) (14.13%)
ROIC
(40.39%) (40.13%) (28.42%) (18.94%)
Return on Tangible Assets
(39.37%) (38.23%) (25.79%) (16.82%)
Average Days of Receivables
— — — —
Free Cash Flow per Share
(5.93) (5.49) (4.98) (3.48)
Free Cash Flow
(40.10) (36.62) (33.76) (23.61)
Other line items

Show all line items

Columns are period end dates